Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4276 in advanced HER2-expressing solid tumors
NCT02576548Phase 1Completed
- Sponsor
- MedImmune
- Start
- Sep 2015
- Primary completion
- May 2018
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MEDI4276 in breast cancer and gastric cancer (GC) (9 arms), sponsored by MedImmune. Primary endpoint: Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs). Started Sep 2015; status: completed.
02
Drugs
MEDI4276
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02576548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576548.